3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with pyridine in 1 studies
Studies (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Trials (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Recent Studies (post-2010) (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Studies (pyridine) | Trials (pyridine) | Recent Studies (post-2010) (pyridine) |
---|---|---|---|---|---|
330 | 40 | 33 | 2,785 | 3 | 1,253 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Castagnoli, N; Dormehl, IC; Hugo, N; Keeve, R; Müller-Gärtner, HW; Oliver, DW; Pond, SM; Van der Schyf, CJ | 1 |
1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and pyridine
Article | Year |
---|---|
Long-term treatment with the tetrahydropyridine analog (HPTP) of haloperidol influences dopamine ligand binding in baboon brain. An [123I]iodobenzamide (IBZM) SPECT study.
Topics: Animals; Benzamides; Binding, Competitive; Brain; Dopamine; Haloperidol; Male; Papio; Pyridines; Pyrrolidines; Time Factors; Tomography, Emission-Computed, Single-Photon | 1996 |